Literature DB >> 35005938

Controlled Modular Multivalent Presentation of the CD40 Ligand on P22 Virus-like Particles Leads to Tunable Amplification of CD40 Signaling.

Cheri Peyton Goodall1, Benjamin Schwarz2, Ekaterina Selivanovitch1, John Avera3, Joseph Wang4, Heini Miettinen5, Trevor Douglas1.   

Abstract

Ligands of the tumor necrosis factor superfamily (TNFSF) are appealing targets for immunotherapy research due to their integral involvement in stimulation or restriction of immune responses. TNFSF-targeted therapies are currently being developed to combat immunologically based diseases and cancer. A crucial determinant of effective TNFSF receptor binding and signaling is the trimeric quaternary structure of the ligand. Additionally, ligand multivalency is essential to propagate strong signaling in effector cells. Thus, designing a synthetic platform to display trimeric TNFSF ligands in a multivalent manner is necessary to further the understanding of ligand-receptor interactions. Viral nanocages have architectures that are amenable to genetic and chemical modifications of both their interior and exterior surfaces. Notably, the exterior surface of virus-like particles can be utilized as a platform for the modular multivalent presentation of target proteins. In this study, we build on previous efforts exploring the bacteriophage P22 virus-like particle for the exterior multivalent modular display of a potent immune-stimulating TNFSF protein, CD40 ligand (CD40L). Using a cell-based reporter system, we quantify the effects of tunable avidity on CD40 signaling by CD40L displayed on the surface of P22 nanocages. Multivalent presentation of CD40L resulted in a 53.6-fold decrease of the half maximal effective concentration (EC50) compared to free CD40L, indicating higher potency. Our results emphasize the power of using P22-based biomimetics to study ligand-receptor interactions within their proper structural context, which may contribute to the development of effective immune modulators.

Entities:  

Keywords:  CD40; CD40L; P22; TNFSF; VLP; biomimetics; multivalency; signaling

Mesh:

Substances:

Year:  2021        PMID: 35005938      PMCID: PMC9136706          DOI: 10.1021/acsabm.1c00718

Source DB:  PubMed          Journal:  ACS Appl Bio Mater        ISSN: 2576-6422


  52 in total

1.  High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.

Authors:  S S Pullen; M E Labadia; R H Ingraham; S M McWhirter; D S Everdeen; T Alber; J J Crute; M R Kehry
Journal:  Biochemistry       Date:  1999-08-03       Impact factor: 3.162

2.  Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity.

Authors:  Christopher M Smith; Nicholas S Wilson; Jason Waithman; Jose A Villadangos; Francis R Carbone; William R Heath; Gabrielle T Belz
Journal:  Nat Immunol       Date:  2004-10-10       Impact factor: 25.606

Review 3.  Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis.

Authors:  Jill Suttles; Robert D Stout
Journal:  Semin Immunol       Date:  2009-06-21       Impact factor: 11.130

4.  Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.

Authors:  Agnes Wyzgol; Nicole Müller; Andrea Fick; Sabine Munkel; Goetz Ulrich Grigoleit; Klaus Pfizenmaier; Harald Wajant
Journal:  J Immunol       Date:  2009-07-13       Impact factor: 5.422

Review 5.  Structural characteristics of CD40 ligand that determine biological function.

Authors:  W C Fanslow; S Srinivasan; R Paxton; M G Gibson; M K Spriggs; R J Armitage
Journal:  Semin Immunol       Date:  1994-10       Impact factor: 11.130

Review 6.  The Immune Revolution: A Case for Priming, Not Checkpoint.

Authors:  Robert H Vonderheide
Journal:  Cancer Cell       Date:  2018-04-09       Impact factor: 31.743

Review 7.  Cracking the BAFF code.

Authors:  Fabienne Mackay; Pascal Schneider
Journal:  Nat Rev Immunol       Date:  2009-07       Impact factor: 53.106

8.  Stepwise molecular display utilizing icosahedral and helical complexes of phage coat and decoration proteins in the development of robust nanoscale display vehicles.

Authors:  Kristin N Parent; Christina T Deedas; Edward H Egelman; Sherwood R Casjens; Timothy S Baker; Carolyn M Teschke
Journal:  Biomaterials       Date:  2012-05-08       Impact factor: 12.479

9.  The phage L capsid decoration protein has a novel OB-fold and an unusual capsid binding strategy.

Authors:  Rebecca L Newcomer; Jason R Schrad; Eddie B Gilcrease; Sherwood R Casjens; Michael Feig; Carolyn M Teschke; Andrei T Alexandrescu; Kristin N Parent
Journal:  Elife       Date:  2019-04-04       Impact factor: 8.140

10.  Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.

Authors:  Kim L Brunekreeft; Corinna Strohm; Marloes J Gooden; Anna A Rybczynska; Hans W Nijman; Götz U Grigoleit; Wijnand Helfrich; Edwin Bremer; Daniela Siegmund; Harald Wajant; Marco de Bruyn
Journal:  Mol Cancer       Date:  2014-04-17       Impact factor: 27.401

View more
  3 in total

1.  A Designer Nanoparticle Platform for Controlled Intracellular Delivery of Bioactive Macromolecules: Inhibition of Ubiquitin-Specific Protease 7 in Breast Cancer Cells.

Authors:  Wynton D McClary; Alexis Catala; Wei Zhang; Fabia Gamboni; Monika Dzieciatkowska; Sachdev S Sidhu; Angelo D'Alessandro; Carlos E Catalano
Journal:  ACS Chem Biol       Date:  2022-07-07       Impact factor: 4.634

2.  Microcompartment assembly around multicomponent fluid cargoes.

Authors:  Lev Tsidilkovski; Farzaneh Mohajerani; Michael F Hagan
Journal:  J Chem Phys       Date:  2022-06-28       Impact factor: 4.304

Review 3.  Temperature-Responsive Nano-Biomaterials from Genetically Encoded Farnesylated Disordered Proteins.

Authors:  Md Shahadat Hossain; Zhe Zhang; Sudhat Ashok; Ashley R Jenks; Christopher J Lynch; James L Hougland; Davoud Mozhdehi
Journal:  ACS Appl Bio Mater       Date:  2022-01-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.